This SEER-Medicare database analysis (n [ 5931) for first-line platinum-based therapy of stage IV NSCLC describes real-world treatment patterns (2007 to mid-2013) by histologic subtype, adverse events (AEs), and associated costs. Carboplatin-doublets were most commonly prescribed; dyspnea/anemia were the most common AEs; mean per-patient-per-month cost was $11,909. Our findings confirm and expand previous study results regarding the AE-related costs of therapy by treatment regimen. Median survival was determined using the Kaplan-Meier method. Results: Surprisingly, only 46% of patients (n ¼ 13,472) with stage IIIB/IV NSCLC received systemic therapy, and 5931 received platinum-based therapy. The mean age was 73 years, with 3354 (57%) males; 1489 (25%) had squamous and 4442 (75%) nonsquamous histology. The most common regimens were carboplatin doublets (70%), including carboplatin/paclitaxel (38%), carboplatin/pemetrexed (12%), carboplatin/gemcitabine (11%), and carboplatin/docetaxel (7%). The median overall survival from first-line therapy initiation was 7.2 months (95% confidence interval, 7.0-7.5 months). Dyspnea and anemia were the most common AEs of interest, whereas atypical pneumonia was associated with the greatest AE-related costs (mean, $5044). The mean total perpatient-per-month cost was $11,909, with AE-related costs comprising 9% of total costs. The highest costs and survival were observed for patients treated with carboplatin/pemetrexed and bevacizumab/carboplatin/paclitaxel. Conclusions: These real-world data illustrate the most common first-line regimens by histology, overall survival, AEs, and some of the high AE-related costs of therapy for advanced NSCLC, and provides extremely useful information for clinicians.
Introduction
Lung cancer is the leading cause of cancer mortality among men and women in the United States (US) and accounts for about 27% of all cancer deaths. A total of 222,500 new cases of lung cancer and 155,870 lung cancer deaths were estimated for 2017. 1 Nonesmall-cell lung cancer (NSCLC), which accounts for about 85% of lung cancer cases, is usually not detected until after regional or distant metastasis (stage IIIB or IV), in which 5-year survival rates diminish to 5% or less. 1, 2 Lung cancer treatment options have vastly increased in recent years, with an expanding arsenal of targeted therapies guided by molecular testing for predictive biomarkers, immunotherapies, and precision local therapies such as stereotactic radiation. [3] [4] [5] Before the approval of first-line immunotherapy, the standard of care in the US for nonsurgical management of advanced/metastatic NSCLC was platinum doublet chemotherapy as first-line therapy, with or without molecular targeted therapy, and with or without maintenance therapy. 6 Platinum agents (cisplatin and carboplatin) have proven effective in combination with several other agents. Randomized controlled trials (RCTs) and meta-analyses have shown that chemotherapy, particularly first-line treatment with platinumbased doublets, is associated with statistically significantly better overall survival (OS) compared with palliative treatment only. 6 First-line chemotherapy is associated with an overall response rate of 30% percent, 4 months of median progression-free survival (PFS), and a median OS of 8 to 11 months. 7, 8 Agents used to treat advanced NSCLC are associated with various adverse event (AE) profiles and toxicities, including hematologic, gastrointestinal, and pulmonary-related toxic effects, among others. 9 These AEs may lead to higher utilization of healthcare resources and expenditures and, in extreme cases, may lead to substantial disability or mortality. 6, [10] [11] [12] [13] [14] [15] Although several real-world studies have examined treatment patterns, OS, and AE-related costs associated with lung cancer, most studies focused on all types of lung cancers combined, 12, [16] [17] [18] [19] [20] or concentrated on all stages of NSCLC collectively [21] [22] [23] or a histologic subtype of NSCLC (ie, squamous or nonsquamous) with little information on OS or AE-related costs. 10, 11, [13] [14] [15] [24] [25] [26] The direct medical costs for lung cancer have reached a staggering $12.1 billion and are expected to increase to $15.2 billion by 2020. 17, 27 Understanding current real-world treatment patterns and healthcare resource utilization (HCRU) is important for understanding the state of therapy and the potential impact of newer therapies, in addition to defining unmet medical needs. 28 The aims of this retrospective observational study were to simultaneously examine real-world treatment patterns, overall and NSCLC-specific survival, AE occurrence, and costs associated with first-line platinum-based chemotherapy in a US Surveillance, Epidemiology, and End Results (SEER)-Medicare population with newly diagnosed advanced (stage IV) NSCLC. This paper describes our findings in the first-line setting, whereas a companion paper describes findings from the second-line setting. 29 
Patients and Methods

SEER-Medicare Database
This retrospective, observational cohort study utilized patient data from the SEER-Medicare linked database, which combines clinical, demographic, and cause of death information on incident cancer cases from the SEER cancer registry with longitudinal administrative Medicare claims. 30, 31 The Medicare claims data 
Outcome Measures
Antineoplastic treatment regimens were captured from claims that utilized the Healthcare Common Procedures Coding System or National Drug Code numbers for specific agents (see Supplemental Table 1 in the online version) . 34, 35 First-line therapy was defined as platinum-based chemotherapy (monotherapy or in combination with other anticancer therapies) that began within 30 days before and 90 days after the diagnosis date, and included all therapy agents for which there was a claim during the next 29 days. First-line therapy ended when a 42-day period with no treatment was observed after the last dose of platinum-based chemotherapy, or if a second drug or regimen started on or after day 30 following the first dose of platinum-based chemotherapy, thus signifying a switch to second-line therapy.
Overall and NSCLC-specific survival were described at 1 year after initiation of first-line therapy (index therapy date) and at the e630 -Clinical Lung Cancer September 2018 1L NSCLC Real World Patterns of Care end of study among all eligible first-line patients, and stratified by the most commonly used regimens. The median survival time (in months) post index therapy date was described for each survival outcome. The number and proportion of eligible patients in the first-line setting who were still alive, died of NSCLC, or died of other causes at the end of study (ie, December 31, 2013), were also presented.
We selected the AEs of interest as the grade 3/4 AEs with incidence 5% as reported in the US prescribing information of drugs used in first-line therapy for advanced/metastatic NSCLC. We restricted the AE list to those requiring HCRU (not lab investigations), based on the Common Terminology Criteria for Adverse Events (CTCAE) description and clinical input. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 36 were used to identify these adverse events and are presented in Supplemental Table 2 (in the online version). The occurrence of AEs of interest was assessed from the start of first-line therapy based on the index therapy date until the last dose of platinum-based chemotherapy (þ42 days) or date of switching to new (second-line) drugs. For each AE of interest, we determined the frequency of the AE and the HCRU event during first-line therapy, including inpatient, emergency, outpatient, skilled nursing facility, and hospice visits. For each HCRU event, we determined the overall number and number per patient per month (PPPM), calculated as the total divided by the total patient-specific days of first-line therapy and multiplied by 30. In addition, we calculated the mean length of inpatient hospitalizations and skilled nursing facility visits.
Claims with an AE of interest coded as the primary diagnosis were attributed to that AE, along with any related claims. For example, the total cost of an inpatient hospitalization, including all claims for that hospitalization, was defined as AE-related if the AE was the primary diagnosis for at least 1 claim. We then determined the mean per-patient cost and the PPPM costs for total HCRU-related costs and for the following categories of costs: (1) AE-related costs (ie, those with the AE as the primary diagnostic code plus related claims) and (2) all NSCLC-related costs, which included the costs identified in claims with a primary diagnosis of lung cancer (ICD-9-CM code, 162.x) 36 as well as all other HCRUrelated costs during first-line therapy. In addition, we calculated the PPPM costs after patients initiated first-line therapy by 5 time intervals (see Supplemental Methods in the online version). Costs were derived from Medicare claims and included the amount paid by Medicare and by patients and other payers.
Statistical Analysis
Summary statistics were used to describe patient demographic and disease-related characteristics, treatment patterns, occurrence of AEs, HCRU, and costs (AE-related and all other NSCLC-related) in the first-line setting. Mean and standard deviation (SD) were reported for continuous variables, whereas frequencies and percentages were reported for categorical variables. The SDs for HCRU and cost variables were calculated using the Poisson distribution assumption. OS and NSCLC-specific survival were analyzed using the Kaplan-Meier method to determine median OS and the associated 95% confidence interval (CI). Costs were evaluated in US dollars (USD), adjusted to 2013 using Consumer Price IndexeAll Urban Consumers. 37 Because of the descriptive, exploratory nature of this study, no formal sample size and power calculations were performed, and no specific hypotheses were tested. Statistical analyses were performed using SAS software, version 9.3 and 9.4 (SAS Institute, Cary, NC).
Results
Study Population
In total, 43,165 patients were identified with first-time diagnosis of stage IIIB/IV NSCLC between 2007 and 2011, and 29,720 had treatment data, among which only 13,742 (46%) received systemic therapy for NSCLC ( Figure 1 ). Of those, 8542 (52%) patients received first-line platinum-based chemotherapy between January 1, 2007, and June 30, 2013, with continuous Medicare enrollment; and 5931 of 8542 (69%) had stage IV NSCLC and met all study eligibility criteria for inclusion in this analysis. The range of first-line therapy initiation dates was January 5, 2007 , to February 24, 2012 . Table 1 displays baseline and clinical characteristics for patients receiving first-line chemotherapy, overall and by histology. Of the 5931 patients, 1489 (25%) had squamous and 4442 (75%) had nonsquamous NSCLC. The age distributions were similar for both cohorts, with a mean of approximately 73 years old. Patients with NSCLC were more likely to be male (57% vs. 43% female), and 88% were white. Slightly more patients with nonsquamous versus squamous histology were from the Northeast (20% vs. 17%), and approximately one-third of patients in each cohort were from the South or from the West. Squamous tumors tended to be larger, with 39% measuring 5.0 cm compared with 25% of nonsquamous tumors. The nonsquamous cohort had fewer comorbidities, with 68% having a Charlson comorbidity index (CCI) of 0% and 4% having a CCI of 3, compared with 60% and 6% having a CCI of 0 and 3, respectively, in the squamous cell cohort (Table 1) . Distant metastasis was observed in 97% of the nonsquamous versus 93% of the squamous cohort.
First-line Therapy for NSCLC Table 2 shows first-line treatment patterns by histology. Over 80% of the squamous cohort was treated with a carboplatin doublet versus 66% of the nonsquamous cohort. The most common treatment combination was carboplatin/paclitaxel, administered to 52% of patients with squamous cell NSCLC and 34% of those with nonsquamous NSCLC. The second most frequently used carboplatin doublet was carboplatin/gemcitabine in the squamous cohort (18%) and carboplatin/pemetrexed in the nonsquamous cohort (16%). Carboplatin triple combinations were used for about 6% of the squamous cohort and 25% of the nonsquamous cohort. Cisplatin doublets accounted for 8% and 6% of treatments for the squamous and nonsquamous cohorts, respectively. Pemetrexed was used for 1% or less of squamous patients. The overall frequency of other first-line regimens was approximately 2% for carboplatin or cisplatin monotherapy, and < 1% for other cisplatin-based therapy and carboplatin/cisplatin combinations ( Table 1) .
The median duration of first-line therapy was 2.8 months overall (range, 2 days to 33.2 months). In the squamous cohort, the median duration was 2.8 months (range, 5 days to 19.5 months), and in the nonsquamous cohort, it was 2.8 months (range, 2 days to 33.2 months). For the most common first-line regimens, the duration of therapy was longest for bevacizumab/carboplatin/paclitaxel in the nonsquamous cohort (median, 4.1 months; range, 5 days to 40.4 months) (see Supplemental Table 3 in the online version). The upper range of carboplatin/paclitaxel therapy duration was longer for the nonsquamous than the squamous cohort (ranged up to 27 vs. 14 months, respectively), whereas the duration for carboplatin/ An asterisk (*) indicates < 11 patients in a cell. A double asterisk (**) indicates > 11 patients in a cell where providing the number would permit determination of the other cell number by subtraction. a Up to five of the most common regimens in each category are reported, so the numbers will not add up to the total n for each regimen category. b The other 4 most common cisplatin-based regimens were bevacizumab/cisplatin/gemcitabine; bevacizumab/cisplatin/paclitaxel; cisplatin/gemcitabine/paclitaxel; and bevacizumab/cisplatin/etoposide. c The 5 most common carboplatin/cisplatin combinations were carboplatin/cisplatin/pemetrexed, carboplatin/cisplatin/gemcitabine, carboplatin/cisplatin, carboplatin/cisplatin/paclitaxel, and bevacizumab/carboplatin/cisplatin/pemetrexed.
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OS
From the initiation of first-line therapy, the median OS was 7.2 months (95% CI, 7.0-7.5 months), and the median NSCLC survival was 8.0 months (95% CI, 7.7-8.3 months). The median OS by histology was 6.7 months (95% CI, 6.3-7.1 months) and 7.5 months (95% CI, 7.2-7.9 months) for the squamous and nonsquamous cohorts, respectively. Figure 2 shows the survival curves overall and for the 5 most common first-line regimens, with the bevacizumab triplet and pemetrexed doublet appearing to show the highest probabilities of survival from 9 to 18 months and pemetrexed doublet showing the highest survival from 18 to 63 months.
At 1 year after initiating first-line therapy, the all-cause mortality was 69%, mortality from lung cancer was 66%, and that from other causes was 10% (not shown; percentages calculated using the Kaplan-Meier method to account for censoring).
The total follow-up time (see Supplemental Table 4 in the online version) was higher for the nonsquamous cohort, with a mean of 14.0 months (median, 9.2 months) versus 12.5 months (median, 8.4 months) for the squamous cohort, with an overall range of about 2 weeks to 7 years. About 94% of patients died during followup, with the main cause of death identified as lung cancer, which accounted for about 82% of deaths overall (4854 of 5931). Other cancer and non-cancer deaths accounted for about 7% and 6% of deaths, respectively (see Supplemental Table 4 in the online version). At the end of the study, 351 patients were alive, including 85 (6%) and 266 (6%) patients with squamous and nonsquamous NSCLC, respectively.
Occurrence of AEs and HCRU and Costs
The 5 most common AEs of interest for total pooled claims were dyspnea, anemia, hypertension, atypical pneumonia, and fatigue. Dyspnea and anemia were the most common, identified in 1811 (30%) and 1536 (26%) patients, respectively, followed by 1050 (18%) patients reporting hypertension, 885 (15%) having atypical pneumonia, and 846 (14%) reporting fatigue (Table 3) . These varied by setting, however, especially for the inpatient setting, where the most common AEs were atypical pneumonia and anemia, and for emergency room visits, where the most common AEs were dyspnea, atypical pneumonia, and fatigue (Table 3) .
The highest mean treatment cost was shown for atypical pneumonia at $5044 for total claims, but was closer to $15,000 and $11,000 for both inpatient and skilled nursing facility visits, respectively (Table 3) (see Supplemental Table 5 in the online version). Anemia was the next highest cost at $2255 for total claims, but was at $7000 for inpatient visits and $15,000 for skilled nursing facility visits. Fatigue was next highest for total claims ($733), especially for skilled nursing facility visits at $7371, followed by dyspnea at $615 for total claims and $9879 for skilled nursing facility visits. Hypertension showed the lowest overall costs at $329 for total claims but was $4967 for inpatient visits.
The frequency of dyspnea and anemia among the total pooled claims for the most common first-line regimens generally followed the above pattern, with dyspnea being the most common AE and anemia the second most common (except for carboplatin/gemcitabine), followed by hypertension, atypical pneumonia, and fatigue (except for carboplatin/pemetrexed) ( Table 3) . Patients who received carboplatin/pemetrexed and carboplatin/gemcitabine displayed the highest outpatient anemia and dyspnea visits, ranging from 22% to 37% of patients.
The highest costs for total pooled claims by treatment regimen were observed for the bevacizumab/carboplatin/paclitaxel triplet for anemia, hypertension, and fatigue, but carboplatin/pemetrexed showed higher costs for dyspnea and atypical pneumonia. The highest inpatient costs were observed for anemia in patients treated with carboplatin/paclitaxel ($10,562) and for atypical pneumonia in patients treated with pemetrexed and paclitaxel combinations, which ranged from approximately $13,000 to $17,000. The highest Mean visits (SD) 1.0 1.0 n/a n/a n/a Mean LOS, d (SD) 2.0 2.0 n/a n/a n/a Mean costs (SD) 2820 2820 n/a n/a n/a outpatient costs were for anemia in patients treated with bevacizumab/carboplatin/paclitaxel ($2777), and for emergency room visits, the highest costs were for patients with atypical pneumonia who received bevacizumab/carboplatin/paclitaxel ($6702). Overall, the mean total PPPM cost for all patients was $11,909 (Table 4 ). The majority (75%) of the total PPPM costs ($8902) were associated with outpatient claims, followed by $1883 (16%) for emergency room visits, $772 (6%) for inpatient visits, $211 (2%) for skilled nursing facility, and $141 (1%) for hospice visits (not shown). The AE-related PPPM costs represented approximately 9% of the total PPPM costs. Drug and administration costs, however, represented 34% of total costs and were proportionally highest for the bevamucizab triplet (51%) and lowest for carboplatin/paclitaxel (5%).
In regards to the most common treatment regimens, the AE-associated PPPM costs ranged from about 7% (carboplatin/ pemetrexed) to 10% (carboplatin/paclitaxel and carboplatin/gemcitabine) of total costs. The total PPPM cost was highest for patients treated with the triplet bevacizumab/carboplatin/paclitexel ($14,126) and carboplatin/pemetrexed ($13,089) and lowest for patients treated with carboplatin/paclitaxel ($8779). The PPPM costs by time interval are presented in Supplemental Table 6 (in the online version).
Discussion
The primary aims of this retrospective observational study were to assess real-world treatment patterns, overall and NSCLC-specific survival, and AE occurrence and costs associated with first-line cancer therapies in a US SEER-Medicare population with stage IV NSCLC, prior to the approval of first-line immunotherapeutics. Three-fourths of NSCLCs in our study population were nonsquamous, and two-thirds of patients received carboplatin doublets (paclitaxel and pemetrexed), with one-fourth receiving a carboplatin triplet. Dyspnea and anemia were the most common AEs of interest in both cohorts, whereas atypical pneumonia and anemia were associated with the highest AE-related costs. The AE-related costs comprised 9% of total costs ($11,909), but it should be noted that these costs were pre-immunotherapy and are relative to the other per-patient costs presented for the prespecified AEs of interest. The majority of claims were associated with outpatient care and emergency visits. Patients treated with carboplatin/pemetrexed and the bevacizumab triplet incurred greater mean costs than patients in the other treatment cohorts.
The first-line treatment regimens in our study were comparable to those in other studies. 9, 24, [38] [39] [40] A recent meta-analysis of 18 studies compared platinum-based chemotherapy regimens and found that for nonsquamous NSCLC, pemetrexed/platinum increased OS compared with gemcitabine/platinum. 39 The median OS ranged from 7.5 to 11.8 months, and a significant increase in OS was observed for pemetrexed/platinum therapy compared with gemcitabine/platinum (hazard ratio [HR], 0.85; 95% CI, 0.73-1.0), which was comparable to our study, but no other significant AEs were similar to those in our study, namely, anemia, pneumonia, and fatigue, but the authors reported difficulty in analyzing these because trials varied in how AEs were defined, measured, and reported; therefore, they recommended that AEs be standardized and reported consistently in order to make future comparisons. Regarding costs, they determined that for patients with squamous NSCLC, paclitaxel, gemcitabine, and docetaxel were all efficacious, but incremental cost-effectiveness ratios comparing interventions with better outcomes to paclitaxel found levels that exceeded costeffectiveness. For patients with nonsquamous NSCLC, pemetrexed combinations provided strong evidence of improved OS but were not necessarily cost-effective. This report was generated in the UK, 39 however, and may have used different standards of clinicaland cost-effectiveness than in the US. In spite of specific recommendations to the contrary, it should be noted that there was a small percentage of patients with squamous NSCLC (about 1% or less) in our study who received pemetrexed with either carboplatin and cisplatin, which shows that the guidelines for pemetrexed, which were changed in 2008 and are now indicated for nonsquamous NSCLC only, 41 are not always being closely adhered to, so that further dissemination and clarification may be needed.
Our study also showed that only 46% of patients received any systemic therapy for their cancer, and only 56% of those received a platinum doublet per guidelines. Reasons for the low use of systemic therapy, such as physician pessimism, older age, or perceived poor prognosis should be further explored.
In our study, the carboplatin/bevacizumab triplet and carboplatin/pemetrexed appeared to have higher OS and greater costs compared with other treatment regimens for nonsquamous NSCLC, which is consistent with other studies. 9, 24, 40, 42 Shah et al 40 examined the cost-effectiveness of first-line pemetrexed/platinum (75% received carboplatin and 25% received cisplatin) and paclitaxel/carboplatin and found a significantly higher mean/median OS for pemetrexed/platinum (190/298 days) compared with paclitaxel/ carboplatin (132/218 days), as well as a 33% lower risk of 1-year disease progression or death. Costs for patients receiving pemetrexed/platinum were also higher than for those receiving paclitaxel/ carboplatin, with a difference of $19,137 (P < .05). However, patients receiving pemetrexed/platinum therapy had lower mean costs than patients receiving triplet therapy (paclitaxel/carboplatin/ bevacizumab). 40 In calculating cost-effectiveness probabilities, the authors determined that pemetrexed/platinum had a 96% higher probability of higher costs/higher effectiveness versus the paclitaxel/ carboplatin doublet for OS. Limitations of that study were that patients were followed only 1 year post-index, and charges for inpatient services and other specialty care were not available, thus underestimating costs. Even so, the overall costs in Shah et al 40 were much higher than our costs but showed similar patterns, and suggests that long-term studies are needed. Spence et al 43 observed a survival advantage in younger patients (<65 years) receiving pemetrexed/bevacizumab combinations. They suggested that combination therapy of a platinum-based agent, such as carboplatin and paclitaxel, could be a reasonable treatment for older patients who may not be candidates for targeted therapy. Future studies and analyses should also examine the impact of patient age on therapy selection and outcomes. In addition, a systematic review by Brown et al 38 evaluated the clinical-and cost-effectiveness of first-line therapy for patients with locally advanced or metastatic NSCLC. In examining mixed-treatment comparisons, they found that, for patients with nonsquamous NSCLC, OS was significantly higher for pemetrexed platinum compared with gemcitabine/platinum (HR, 0.85; 95% CI, 0.74-0.98) and for docetaxel/platinum compared with paclitaxel/platinum (HR, 0.79; 95% CI, 0.66-0.93). It should be noted, however, that poor quality of the studies and lack of evidence for all drug comparisons limited the data analysis. Outcomes and AEs were also not consistently combined across the trials. They recommend that future lung cancer trials be adequately powered and reflect the influence of factors such as histology, genetics, and new prognostic biomarkers. This study provided a detailed description of the occurrence and cost of AEs by treatment type and setting, which has not been previously done and is important for clinical practice. Pilkington et al 39 provided a list of AEs but did not include the type of setting, and they acknowledged many limitations in their analysis, as previously noted. Our analysis showed the highest overall AEs for dyspnea, anemia, and atypical pneumonia, but these varied depending on the treatment regimen and setting. Overall, these costs were highest in the inpatient and skilled nursing facility settings, as would be expected. Perhaps, in order to reduce overall treatment costs, more efforts could be made to find ways to prevent these complications from becoming extreme enough that patients have to enter these high-cost settings. Also, perhaps a lower cost treatment regimen could be substituted for patients with certain complications based on these findings. Future studies in diverse populations should attempt to perform similar analyses as well.
The main strengths of our study are that it includes the most recent data available from SEER-Medicare on use of resources and costs for the study period, which preceded the widespread use of immunotherapy, and evaluates treatment patterns by NSCLC histology. The SEER-Medicare data have been validated and widely adopted for this type of study. 30 Our population of SEER-Medicare patients aged 65 years captured a large proportion of patients with NSCLC in SEER catchment areas, with an average diagnosis age of about 70 years, and approximately two-thirds of diagnoses made at 65 years. 44 Demographic and clinical characteristics of our study population were consistent with the general population of patients with advanced NSCLC, including the division of approximately one-third versus two-thirds squamous versus nonsquamous histology, respectively, and showing adenocarcinoma as the most common histologic type. 45 The majority of patients with squamous NSCLC in our study were male, whereas patients with nonsquamous NSCLC were almost evenly divided between males and females. Overall, 46% of patients initially identified with stage IIIB/IV NSCLC received chemotherapy, which is higher than in earlier reports of advanced/metastatic NSCLC using the SEER-Medicare linked database, 13, 46 and similar to the 46% of patients aged 65 years who received chemotherapy in a study using 2002 through 2007 data from HMOs participating in the Cancer Research Network. 25 There were several study limitations that deserve mention. The SEER-Medicare database did not include information on smoking status or performance status. Additionally, the database lacked specific information on maintenance therapy, and we could not determine the number of cycles delivered, but we did have treatment duration, however, as a proxy. Also, AEs were identified from ICD-9 codes and thus may not have been caused by the cancer or anticancer therapy, so we may not have identified the true overall rates. Moreover, because we were able to include only patients with NSCLC diagnosed through 2011 and Medicare claims data through 2013, we could identify only patients with initial diagnosis of stage IIIB/IV NSCLC, thus excluding those with NSCLC recurrence or progression from earlier to advanced stages. Furthermore, this study was restricted to patients who received first-line platinum-based chemotherapy and hence may not be representative of current realworld treatment patterns that include targeted therapy and immunotherapy. Also, only patients 65 years and older were included in the database so our results could not be generalized to younger ages. Finally, because biomarker information was not available in the database, we were not able to analyze treatment patterns by biomarker status.
In conclusion, we believe this study effectively captured realworld first-line treatment patterns for stage IV NSCLC, the most common AEs, and some of the high costs associated with treatment and AEs, such as atypical pneumonia and anemia, which previous studies have not adequately captured. Despite several limitations, our study confirmed and expanded previous findings, including that the pemetrexed-carboplatin doublet and carboplatin-bevacizumab triplet are often the most costly but may be the most clinically effective treatments for nonsquamous NSCLC, with pemetrexed showing better long-term survival. This study also suggests that guidelines for appropriate use of treatments may need to be better discerned, and the reasons for the low use of systemic therapy should also be explored. Further studies should also examine a greater age range, smoking history, maintenance therapy information, and the use of oral drugs and other newer targeted therapies in diverse populations and their impact on resource utilization.
Clinical Practice Points
Understanding current real-world treatment patterns and HCRU for NSCLC is necessary for understanding the state of current therapy and the potential impact of newer therapies, in addition to defining unmet medical needs.
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We describe the most common first-line regimens by histology, OS, AEs, and the cost of therapy for 5931 patients 65 years with first-time stage IV NSCLC. Previous studies either focused on all lung cancers combined, omitted histologic subtype (squamous/nonsquamous), and provided little information on OS or AE-related costs. Our study includes detailed histologic subtypes, OS, and shows AEs by cost and treatment regimen, which is critical information for clinicians to know. Our findings show that only 46% of patients with stage IIIB/IV NSCLC received systemic therapy, with, carboplatin doublets the most common regimen, specifically carboplatin/paclitaxel. Among the prespecified AEs, dyspnea and anemia were the most common AEs, with anemia and atypical pneumonia showing the greatest AE-related costs, especially the bevacizumab triplet and carboplatin doublet (also showing higher survival). The mean total per-patient-per-month cost was $11,909, with AE-related costs comprising 9% of total costs. Our findings on AEs, costs, and survival by histology and treatment regimen provide important information for clinicians regarding current and future use of first-line NSCLC therapy. Recommendations for better dissemination of guidelines and appropriate use of treatments are also provided, with suggestions for further exploration of reasons for the low use of systemic therapy and overall suggestions for future research.
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